NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results
Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No...